Cranbrook Wealth Management LLC Sells 134 Shares of Stryker Co. (NYSE:SYK)

Cranbrook Wealth Management LLC decreased its position in Stryker Co. (NYSE:SYK) by 2.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 4,841 shares of the medical technology company’s stock after selling 134 shares during the period. Cranbrook Wealth Management LLC’s holdings in Stryker were worth $1,802,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. J. W. Coons Advisors LLC lifted its holdings in Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC lifted its holdings in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after buying an additional 27 shares during the period. Opal Wealth Advisors LLC lifted its holdings in Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC lifted its holdings in Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after buying an additional 28 shares during the period. Finally, JFS Wealth Advisors LLC raised its holdings in shares of Stryker by 4.4% during the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company’s stock valued at $247,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.3%

NYSE:SYK opened at $384.15 on Friday. The company has a 50-day moving average price of $370.10 and a 200-day moving average price of $376.03. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $146.63 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. During the same period last year, the company posted $2.50 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. Stryker’s dividend payout ratio is 45.41%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Roth Mkm upped their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a report on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.